Sirolimus interferes with iron homeostasis in renal transplant recipients

被引:65
|
作者
Maiorano, Annamaria
Stallone, Giovanni
Schena, Antonio
Infante, Barbara
Pontrelli, Paola
Schena, Francesco Paolo
Grandaliano, Giuseppe
机构
[1] Univ Bari, Div Nephrol, Dept Emergency & Transplantat, I-70124 Bari, Italy
[2] Univ Foggia, Div Nephrol, Dept Biomed Sci, Foggia, Italy
关键词
sirolimus; anemia; renal transplantation; hepcidin;
D O I
10.1097/01.tp.0000235545.49391.1b
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Sirolimus is an immunosuppressive drug whose use is frequently associated with anemia. A pathogenic link between sirolimus-induced anemia and the appearance of an inflammatory state was recently suggested. Because inflammation-related anemia is characterized by a functional iron deficiency, we investigated whether sirolimus may influence iron homeostasis and serum levels of hepcidin, a key mediator of inflammation-related-anemia. Methods. To this purpose, 42 consecutive transplanted patients with biopsy-proven chronic allograft nephropathy were randomized (2:1 ratio) to receive either a 40% cyclosporine reduction (group A, 14 patients) or immediate cyclosporine withdrawal and sirolimus introduction (group B, 28 patients). Hemoglobin levels and iron status were evaluated 6 months before and after randomization. Results. The two groups had similar hemoglobin levels and iron status at baseline. We did not observe any significant change in hemoglobin and iron status in group A patients after randomization. On the contrary, we observed a significant reduction of hemoglobin without any change of red blood cell count after sirolimus introduction, with a significant reduction of mean corpuscular volume and mean corpuscular hemoglobin. Serum iron and transferrin saturation (TSAT) levels were markedly reduced after the switch, while ferritin serum concentrations remained stable. Although sirolimus-induced anemia was recently suggested to resemble inflammation-related anemia, hepcidin serum levels were similar in the two groups after randomization. None of group A and eight of group B patients presented a TSAT < 20 and were given iron supplementation after randomization, in all of them oral iron therapy did not influence either hemoglobin or serum iron levels. Conclusion. We demonstrated that sirolimus-induced anemia is independent of the drug antiproliferative effect and does not present the features of inflammation-related anemia. This event maybe due to the direct influence of sirolimus on iron homeostasis.
引用
收藏
页码:908 / 912
页数:5
相关论文
共 50 条
  • [41] Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer
    Campbell, S. B.
    Walker, R.
    Tai, S. See
    Jiang, Q.
    Russ, G. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (05) : 1146 - 1156
  • [42] mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
    Jefferies, Reece
    Puttagunta, Harish
    Krishnan, Anoushka
    Irish, Ashley
    Swaminathan, Ramyasuda
    Olynyk, John K.
    FRONTIERS IN MEDICINE, 2022, 9
  • [43] Effects of conversion from sirolimus oral solution to tablets in stable Taiwanese renal transplant recipients
    Wu, FLL
    Tsai, MK
    Sun, SW
    Chen, RRL
    Huang, JD
    Lee, PH
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2005, 104 (01) : 22 - 28
  • [44] Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy
    Schachter, Asher D.
    Benfield, Mark R.
    Wyatt, Robert J.
    Grimm, Paul C.
    Fennell, Robert S.
    Herrin, John T.
    Lirenman, David S.
    McDonald, Ruth A.
    Munoz-Arizpe, Ricardo
    Harmon, William E.
    PEDIATRIC TRANSPLANTATION, 2006, 10 (08) : 914 - 919
  • [45] ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients
    Lee, Jun
    Huang, Hongfeng
    Chen, Ying
    Lu, Xiaoyang
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2014, 35 (03) : 164 - 172
  • [46] Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus
    Gallon, Lorenzo
    Traitanon, Opas
    Sustento-Reodica, Nedjema
    Leventhal, Joseph
    Ansari, M. Javeed
    Gehrau, Ricardo C.
    Ariyamuthu, Venkatesh
    De Serres, Sacha A.
    Alvarado, Antonio
    Chhabra, Darshika
    Mathew, James M.
    Najafian, Nader
    Mas, Valeria
    KIDNEY INTERNATIONAL, 2015, 87 (04) : 828 - 838
  • [47] Case Report: Sirolimus Therapy in Orthotopic Liver Transplant (OLT) Recipients with Acute Renal Insufficiency
    Marzia Montalbano
    Guy W. Neff
    Grabriella Slapak-Green
    Thierry Berney
    Douglas Meyer
    Digestive Diseases and Sciences, 2004, 49 : 1986 - 1989
  • [48] Kaposi's sarcoma in renal transplant recipients, sirolimus utility: case report and literature revision
    Karina Garcia, Paola
    Cordoba Buritica, Juan Pablo
    Patricia Rodriguez, Martha
    Enrique Echeverri, Jorge
    Lozano, Eyner
    Benavides, Carlos
    UNIVERSITAS MEDICA, 2011, 52 (02): : 209 - 218
  • [49] The effect of ABCB1 polymorphism on sirolimus in renal transplant recipients: a meta-analysis
    Shao, Shuai
    Hu, Lei
    Hang, Zaigang
    Hou, Kelu
    Fang, Huihui
    Zhang, Guijie
    Feng, Yufei
    Huang, Lin
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (02) : 673 - +
  • [50] Conversion between sirolimus and everolimus in heart transplant recipients
    Wert, Thomas J.
    Heeney, Stephanie
    Morrison, Maddy
    CLINICAL TRANSPLANTATION, 2023, 37 (11)